# White-Label AI Healthcare Diagnostic Tool | Build vs Buy | RapidDev

- Tool: AI Implementations
- Last updated: June 2026

## TL;DR

Three paths: buy white-label SaaS (none exist — Aidoc, Viz.ai are FDA-cleared products, not resellable), hire RapidDev ($80K–$250K+, 24–52 weeks, excluding FDA), or build yourself (demo only — serving real patients without FDA clearance is illegal). The decisive number: any AI feature that outputs 'patient may have condition X' likely triggers FDA 510(k) at $25K–$250K+ in submission costs. Hire-agency with a regulatory consultant is the only defensible path.

## Frequently asked questions

### How much does it cost to build a white-label AI healthcare diagnostic tool?

$80,000–$250,000 for the software alone with RapidDev. FDA 510(k) submission adds $25,000–$250,000+. Clinical validation studies add $50,000–$500,000. Realistic all-in budget from concept to FDA-cleared product: $200,000–$1,000,000+ over 2–3 years. This is a venture-backed or health-system-funded category — not a solo-founder category.

### How long does it take to ship?

24–52 weeks for the software alone, excluding FDA timeline. FDA 510(k) review adds 6–18 months. Total from concept to cleared product: typically 2–3 years. The software timeline and the FDA timeline overlap partially — you can begin the submission process while the software is being built, but you cannot launch clinically until clearance is granted.

### Can RapidDev build this for my health system?

Yes, for the software component. RapidDev has built 600+ applications including HIPAA-covered infrastructure. However, we strongly recommend engaging a healthcare regulatory consultant before scoping the software — the regulatory pathway (510(k) vs. non-device CDS) directly determines the software architecture. Book a free 30-minute consultation.

### When does AI clinical software require FDA clearance?

When it makes specific diagnostic or treatment recommendations. FDA's January 2026 revised CDS guidance defines the non-device exemption narrowly: the software must display the basis of its recommendations so a clinician can independently verify them, AND must be used only by or for clinicians. Any consumer-facing AI that interprets symptoms and suggests conditions is almost certainly SaMD requiring 510(k).

### What is the Pieces Technologies settlement and why does it matter?

The Texas AG settled with Pieces Technologies in 2024 over accuracy claims for a clinical AI product that had a higher hallucination rate than advertised. The settlement established that overstating clinical AI accuracy is a consumer-protection violation enforceable by state AGs, not just an ethical issue. Any marketing claim about diagnostic accuracy must be validated in published clinical studies and accurately represented.

### What is a non-device CDS product, and is that a safe alternative to a diagnostic tool?

Non-device clinical decision support software matches patient data to current clinical guidelines and displays the full source basis for a licensed clinician to independently verify. It is not patient-facing and does not make specific diagnostic recommendations. FDA's January 2026 guidance identifies four criteria that must all be met for the non-device exemption: not intended for diagnosis/treatment; displays the basis for recommendation; clinician can independently review the basis; intended only for use by or for clinicians. This is the safe scope for a custom CDS build — but it still requires HIPAA BAA and a regulatory consultant review.

---

Source: https://www.rapidevelopers.com/ai-implementation/ai-based-healthcare-diagnostic-tool-ai-white-label
© RapidDev — https://www.rapidevelopers.com/ai-implementation/ai-based-healthcare-diagnostic-tool-ai-white-label